Condition: Advanced Non-Small Cell Lung Cancer With MET Mutations · Sponsor: Criterium, Inc.
This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer with central nervous system metastasis. In some patients, who have developed resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how effective tepotinib is in combination with TKIs. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C., District of Columbia, United States | — |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | — |
| University of Washington | Seattle, Washington, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04739358